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Abstract Maurotoxin (MTX) is a 34-residue toxin that has
been isolated from the venom of the chactidae scorpion Scorpio
maurus palmatus, and characterized. Together with Pi1 and
HsTx1, MTX belongs to a family of short-chain four-disulfide-
bridged scorpion toxins acting on potassium channels. However,
contrary to other members of this family, MTX exhibits an
uncommon disulfide bridge organization of the type C1^C5, C2^
C6, C3^C4 and C7^C8, versus C1^C5, C2^C6, C3^C7 and C4^
C8 for both Pi1 and HsTx1. Here, we report that the substitution
of MTX proline residues located at positions 12 and/or 20,
adjacent to C3 (Cys13) and C4 (Cys19), results in conventional
Pi1- and HsTx1-like arrangement of the half-cystine pairings. In
this case, this novel disulfide bridge arrangement is without
obvious incidence on the overall three-dimensional structure of
the toxin. Pharmacological assays of this structural analog,
[A12,A20]MTX, reveal that the blocking activities on Shaker B
and rat Kv1.2 channels remain potent whereas the peptide
becomes inactive on rat Kv1.3. These data indicate, for the first
time, that discrete point mutations in MTX can result in a
marked reorganization of the half-cystine pairings, accompanied
with a novel pharmacological profile for the analog. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Maurotoxin (MTX), a toxin from the venom of the Tuni-
sian chactidae scorpion Scorpio maurus palmatus, is a 34-mer
peptide cross-linked by four disul¢de bridges [1]. MTX be-
longs to a distinct family of short-chain scorpion toxins
with less than 40 residues, that are active on several potassium
channel subtypes (Kv and SK channels). Contrary to most
short-chain K channel-acting scorpion toxins, this family
can be distinguished by the presence of an additional disul¢de
bridge (four instead of the three commonly present in such
toxins). This structural class also includes Pi1 and HsTx1
from the venoms of the scorpions Pandinus imperator [2]
and Heterometrus spinnifer [3], respectively. These toxins share
from 53 to 68% sequence identity with MTX but display dif-
ferent pharmacological selectivities. For instance, MTX and
Pi1 are both active on apamin-sensitive SK channels, whereas
HsTx1 is reportedly inactive on this channel type. Also, MTX
was found to be active on rat Kv1.3 channels contrary to
synthetic Pi1 [4]. Interestingly, MTX structurally di¡ers
from Pi1 and HsTx1, but also from other ‘classical’ three-
disul¢de-bridged scorpion toxins, by its unique disul¢de
bridge pattern. In three-disul¢de-bridged toxins, the half-cys-
tine pairings are of the type C1^C4, C2^C5 and C3^C6 (e.g.
charybdotoxin, P05, agitoxin 2, leiurotoxin 1). In short-chain
four-disul¢de-bridged toxins, this pattern is altered by the
insertion of two additional half-cystines within the amino
acid sequence, one located after C3 and the other after C6.
As a result, two novel patterns of the disul¢de bridges are
experimentally found depending on the toxin: (i) a pattern
of the type C1^C5, C2^C6, C3^C7 and C4^C8 in both Pi1
and HsTx1 (which corresponds to an organization similar to
that observed in three-disul¢de-bridged toxins) and (ii) an
uncommon pattern of the type C1^C5, C2^C6, C3^C4 and
C7^C8 in MTX. These two patterns possess in common the
¢rst two disul¢de bridges but di¡er in the two remaining
disul¢des. Though di¡erences in pharmacological properties
between short-chain four-disul¢de-bridged toxins obviously
rely on their distinct amino acid sequences, it is also likely
that changes in half-cystine pairings may contribute to dis-
crete conformational alterations and repositioning of key res-
idues that are involved in toxin selectivity. In MTX, we no-
ticed that the two proline residues in positions 12 and 20 are
adjacent to the non-conventional disul¢de bridge C3^C4
(Cys13^Cys19). Though these residues are also present in ho-
mologous positions in HsTx1, Pi1 and Pi4, we expected that
structural variations induced by the mutagenesis of these pro-
line residues could favor the shift from a MTX-like to a Pi1/
HsTx1-like disul¢de bridge pattern. To test this hypothesis,
we chemically synthesized by the solid-phase method an MTX
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analog ([A12,A20]MTX) in which the two proline residues are
substituted by alanine residues. Our data show that these
substitutions are responsible for a Pi1- and HsTx1-like rear-
rangement of the half-cystine pairings of MTX accompanied
by subtle changes in pharmacological activity.
2. Materials and methods
2.1. Materials
N-K-£uorenylmethyloxycarbonyl (N-K-Fmoc)-L-amino acids,
Fmoc-amide resin and reagents used for peptide synthesis were ob-
tained from Perkin-Elmer. Solvents were analytical grade products
from SDS. Enzymes (trypsin and chymotrypsin) were obtained from
Boehringer Mannheim.
2.2. Chemical synthesis and physicochemical characterization of
[A12,A20]MTX
[A12,A20]MTX was obtained by the solid-phase method [5] using a
peptide synthesizer (Model 433A, Applied Biosystems). Peptide chains
were assembled stepwise on 0.25 meq of Fmoc-amide resin (0.89 meq
of amino group/g) using 1 mmol of Fmoc-amino acid derivatives. N-
K-amino groups were deprotected by treatment with 18 and 20% (v/v)
piperidine/N-methylpyrrolidone for 3 and 8 min, respectively. The
Fmoc-amino acid derivatives were coupled (20 min) as their hydroxy-
benzotriazole active esters in N-methylpyrrolidone (four-fold excess).
The peptide resin (about 2 g) was treated for 2.5 h at room temper-
ature with a mixture of tri£uoroacetic acid (TFA)/H2O/thioanisole/
ethanedithiol (88:5:5:2, v/v) in the presence of crystalline phenol
(2.25 g). After lyophilization, the crude reduced peptide (2 mM) was
oxidized in 200 mM Tris^HCl bu¡er, pH 8.3. [A12,A20]MTX was
puri¢ed by reversed-phase high-pressure liquid chromatography
(HPLC) (Perkin-Elmer, C18 Aquapore ODS 20 Wm, 250U10 mm)
by means of a 60-min linear gradient of 0.08% (v/v) TFA/0^30%
acetonitrile in 0.1% (v/v) TFA/H2O at a £ow rate of 6 ml/min
(V= 230 nm). The homogeneity and identity of [A12,A20]MTX was
assessed by: (i) analytical C18 reversed-phase HPLC (Merck, C18 Li-
chrospher 5 Wm, 4U200 mm) using a 60-min linear gradient of 0.08%
(v/v) TFA/0^60% acetonitrile in 0.1% (v/v) TFA/H2O at a £ow rate of
1 ml/min; (ii) amino acid analysis after acidolysis (6 N HCl/2% (w/v)
phenol, 20 h, 118‡C, N2 atmosphere); and (iii) mass determination by
matrix-assisted laser desorption-ionization time-of-£ight (MALDI-
TOF) mass spectrometry.
2.3. Structural characterization of [A12,A20]MTX: assignment of
half-cystine pairings by enzyme cleavage and Edman sequencing
analysis
[A12,A20]MTX (800 Wg) was incubated either with a mixture of
trypsin and chymotrypsin at 10% (w/w) in 0.2 M Tris^HCl, pH 7.1,
for 12 h at 37‡C. The peptide fragments were then puri¢ed by ana-
lytical reversed-phase HPLC (Vydac, C18 5 Wm column, 4U150 mm)
with a 60-min linear gradient of 0.08% (v/v) TFA/0^60% acetonitrile
in 0.1% (v/v) TFA/H2O at a £ow rate of 1 ml/min (V= 230 nm). The
peptide fragments were hydrolyzed (6 N HCl/phenol) and their amino
acid content was analyzed (Beckman, System 6300 amino acid ana-
lyzer). The peptides were also characterized by mass spectrometry
analysis (RP-DE Voyager, Perseptive Biosystems) and Edman se-
quencing (Applied Biosystems 470A).
2.4. Conformational analysis of [A12,A20]MTX by one-dimensional
(1D) nuclear magnetic resonance (NMR)
5 mg of MTX or its structural analog, [A12,A20]MTX, were dis-
solved in 0.5 ml of a mixture of H2O:D2O (9:1, v/v). All 1H-NMR
measurements were obtained on a Bruker DRX 500 spectrometer
equipped with an HCN probe and self-shielded triple axis gradients
were used. The experiments were performed at 300 K.
2.5. Molecular modeling
Molecular modeling was performed using MSI InsightII(98) soft-
ware package on an O2 silicon graphics workstation. We used the
Biopolymer module for proline mutations and disul¢de bridge reor-
ganization and the Discover program for energy minimization. The
molecular mechanics method has been applied with the parameters of
the consistent valence force ¢eld (CVFF). Starting geometries of MTX
and [A12,A20]MTX were preliminary minimized by the steepest de-
scent method, then re¢ned by the conjugate gradient method until
the ¢nal root-mean-square derivative of the energy was less than
0.001 kcal mol31 Aî 31 in each case.
2.6. Binding assay of [125I]apamin and competition by
[A12,A20]MTX onto rat brain synaptosomes
Rat brain synaptosomes (P2 fraction) were prepared as described
by Gray and Whittaker [6]. The protein content was determined by a
modi¢ed Lowry method. [125I]apamin (2000 Ci/mmol) was obtained
according to Seagar et al. [7]. Aliquots of 50 Wl 0.1 nM [125I]apamin
were added to 400 Wl synaptosome suspension (0.4 mg protein/ml).
Samples were incubated for 1 h at 4‡C with 50 Wl of various concen-
trations of [A12,A20]MTX in 500 Wl ¢nal volume. The incubation
bu¡er was 25 mM Tris^HCl, 10 mM KCl, pH 7.2. The samples
were centrifuged and the resulting pellets were washed three times
in 1 ml of the same bu¡er. Bound radioactivity was determined by
Q counting (Packard Crystal II). The values expressed are the means of
triplicate experiments þ S.D. Non-speci¢c binding, less than 10% of
the total binding, was determined in the presence of an excess
(10 nM) of unlabeled apamin.
2.7. Oocyte preparation and electrophysiological recordings
Xenopus laevis oocytes were prepared for cRNA injection and elec-
trophysiological recordings as described [8]. Plasmids coding for K
channels were linearized with SmaI (Shaker B), NotI (rat Kv1.1), XbaI
(rat Kv1.2) and EcoRI (rat Kv1.3), and transcribed into cRNA with
T7 or SP6 (mMessage mMachine kit, Ambion). The cRNA were
stored frozen in H2O at 380‡C at 1 Wg/Wl. Cells were micro-injected
2 days later with 50 nl of cRNA (0.1^0.2 Wg/Wl Shaker B, rat Kv1.1,
rat Kv1.2 or rat Kv1.3 channels) and incubated 2^6 days at 16‡C into
a de¢ned nutrient oocyte medium [9] before current recordings. Both
current and voltage electrodes were ¢lled with 140 mM KCl and had
resistances ranging from 0.5 to 1 M6. Currents were recorded using a
voltage-clamp ampli¢er (GeneClamp 500, Axon Instruments, Burlin-
game, CA, USA) interfaced with a 16-bit AD/DA converter (Digidata
1200A, Axon Instruments) for acquisition and voltage protocol appli-
cation. Voltage pulses were delivered every 15 s from a holding po-
tential of 380 mV. Current signals were captured at 10 kHz and low
pass-¢ltered at 2 kHz using an eight-pole Bessel ¢lter. The extracellu-
lar recording solution contained (in mM): 88 NaCl, 10 KCl, 2 MgCl2,
0.5 CaCl2, 0.5 ni£umic acid, 5 HEPES, pH 7.4 (NaOH). Leak and
capacitive currents were subtracted on-line by a P/4 protocol. Peptide
solutions were perfused in the recording chamber at a £ow rate of
2 ml/min using a ValveBank4 apparatus (Automate Scienti¢c). 0.1%
bovine serum albumin was added to the recording and perfusion so-
lutions to prevent [A12,A20]MTX loss to the plastic chamber and
tubules. Data analysis was performed using pCLAMP 6.0.3 software
(Axon Instruments, Foster City, CA, USA). The results are presented
as mean þ S.E.M.
3. Results and discussion
The amino acid sequence of MTX is shown in Fig. 1. The
arrangement of half-cystines is of the type C1^C5 (Cys3^
Cys24), C2^C6 (Cys9^Cys29), C3^C4 (Cys13^Cys19) and C7^
C8 (Cys31^Cys34). This disul¢de bridge organization is un-
common amongst known scorpion toxins since ‘conventional’
pairings are either of the type C1^C4, C2^C5 and C3^C6 for
three-disul¢de-bridged toxins or C1^C5, C2^C6, C3^C7 and
C4^C8 for toxins cross-linked by four disul¢de bridges (Pi1-
and HsTx1-like toxins). The reticulation of MTX is peculiar
with regard to the two last disul¢de bridges C3^C4 (Cys13^
Cys19) and C7^C8 (Cys31^Cys34) since they form cyclic do-
mains with contiguous half-cystines. In MTX, we hypothe-
sized that mutations of both or either one of the two proline
residues in positions 12 and 20 may be accompanied by struc-
tural variations that could prevent the formation of the C3^
C4 disul¢de bridge. Pi1 and HsTx1-like half-cystine pairings
could result from these mutations in agreement with the fact
that Pi7, which lacks one of the homologous proline residue,
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presents a bridging that is similar to those of Pi1 and HsTx1
[10]. These proline residues are engaged in cis or trans -CON-
tertiary amide bonds with their preceding amino acid residues
instead of forming standard -CONH- peptide bonds. There-
fore, we designed and chemically synthesized [A12,A20]MTX,
a structural analog of the toxin in which prolines were re-
placed by alanine residues (Fig. 1), and characterized its
half-cystine pairings and pharmacology. In case of proline
residues playing a pivotal role in the MTX half-cystine pair-
ings, one should expect a reorganization of the disul¢de
bridges in [A12,A20]MTX towards the Pi1/HsTx1 pattern.
Stepwise assembly of [A12,A20]MTX was achieved on 0.25
mmol Fmoc-amide resin by means of optimized Fmoc/t-butyl
chemistry [1,11]. The overall yield of peptide chain assembly
was 80%. The pro¢les of elution by analytical C18 reversed-
phase HPLC of the crude reduced peptide after ¢nal acidol-
ysis is shown in Fig. 2A. The crude peptide was folded/oxi-
dized by 48 h air exposure, and puri¢ed to homogeneity by
preparative C18 reversed-phase HPLC. Mass spectrometry
analysis of [A12,A20]MTX gave an experimental Mr (M+H)
of 3561.5, in good agreement with the deduced Mr (M+H)
of 3561.2 for this analog (Fig. 2B). Amino acid analysis of
[A12,A20]MTX after acidolysis provides an amino acid content
which agreed with the deduced values. To address the pattern
of half-cystine connections, [A12,A20]MTX was cleaved by a
mixture of trypsin and chymotrypsin. An analytical C18 re-
versed-phase HPLC pro¢le of [A12,A20]MTX enzyme diges-
tions shows several proteolytic fragments (Fig. 2C). The pep-
tide fragments were collected, and characterized by means of
amino acid analysis, mass spectrometry, and Edman sequenc-
ing techniques (Fig. 2D). The half-cystine pairings were un-
ambiguously mapped as Cys3^Cys24 (C1^C5), Cys9^Cys29
(C2^C6), Cys13^Cys31 (C3^C7) and Cys19^Cys34 (C4^C8).
This pattern shown in Fig. 2E is of the Pi1/HsTx1 type instead
of being of the MTX type. Similarly, we also synthesized and
characterized the singly point-mutated analogs, [A12]MTX
and [A20]MTX. The results obtained from identical enzyme
treatments demonstrate that both peptides folded like
[A12,A20]MTX, the Pi1/HsTx1-like pattern (data not shown).
This indicates that [A12,A20]MTX should be structured
according to the common K/L sca¡old of scorpion toxins
(an K-helix connected by two disul¢de bridges to an antipar-
allel L-sheet structure) since the disul¢de bridge arrangement
adopted was of the ‘conventional’ pattern instead of being
random. To assess whether proline mutations could be re-
sponsible for inducing signi¢cant conformational changes in
the MTX analog, we performed comparative 1D 1H-NMR
analyses of MTX (Fig. 3A, left) and [A12,A20]MTX (Fig.
3A, right). In addition, an energy-minimized model of
[A12,A20]MTX (Fig. 3B, right) has been constructed on the
basis of the experimentally mapped disul¢de bridges, and
compared with the 3D structure of MTX (Fig. 3B, left). To-
gether, the structural data indicate that the overall K/L scaf-
fold of scorpion toxin is maintained in [A12,A20]MTX, in
Fig. 1. Amino acid sequences, in one-letter code, of natural MTX
(top) and its structural analog, [A12,A20]MTX (bottom). In the case
of MTX, the disul¢de bridges are shown in lines [1]. The positions
of half-cystines are numbered from 1 to 8.
Fig. 2. [A12,A20]MTX at di¡erent stages of its chemical synthesis
and physicochemical characterization. A: Analytical C18 reversed-
phase HPLC pro¢les of crude reduced peptide after TFA cleavage
(left), crude peptide after folding/oxidation (middle) and puri¢ed
folded [A12,A20]MTX (right). B: The identity of the peptide was
con¢rmed by both MALDI-TOF mass spectrometry analysis and
amino acid content determination. C: Analytical C18 reversed-phase
HPLC pro¢le of [A12,A20]MTX enzyme digestion. The retention
times of the uncleaved peptide and proteolytic fragments providing
data on the half-cystine pairings are indicated. D: Assignment of
the half-cystine pairings by analysis of the peptide fragments ob-
tained by trypsin/chymotrypsin treatment of [A12,A20]MTX. After
enzyme-based cleavage, the peptide fragments were puri¢ed by ana-
lytical C18 reversed-phase HPLC and characterized by amino acid
analysis, Edman sequencing and mass spectrometry. The peptide se-
quences deduced from these analyses are shown. Retention times in
HPLC, deduced and experimental Mr values of the proteolytic frag-
ments, and established half-cystine pairings are indicated. E: Com-
plete disul¢de bridge pattern of synthetic [A12,A20]MTX, as experi-
mentally determined by enzyme-based cleavage. The positions of
half-cystines residues are indicated by numbers. The disul¢de
bridges are shown in lines. For conditions, see in Materials and
methods.
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agreement with the concept that this sca¡old is not dramati-
cally altered by the two distinct disul¢de bridge patterns that
are observed in MTX and Pi1/HsTx1. According to the model
of [A12,A20]MTX, a marked structural di¡erence between
MTX and [A12,A20]MTX appears to be the relative angle
between the axis of the K-helix and the axis of the L-sheet.
This angle is 50‡ in MTX, whereas it is close to 25‡ in
[A12,A20]MTX.
Such a decrease in the angle between the axis of the K-helix
and the axis of the L-sheet has also been observed in a three-
disul¢de-bridged MTX analog, [Abu19, Abu34]MTX, which
was designed to restore the consensus motif of scorpion toxins
[12]. In this analog, which possesses half-cystine pairings of
the type C1-C4, C2-C5 and C3-C6, the angle is of 0‡. This
change in angle was correlated with modi¢cations in pharma-
cology. Therefore, we studied the pharmacological activity of
[A12,A20]MTX onto apamin-sensitive SK and a number of
voltage-gated Kv channels. We ¢rst tested the ability of
[A12,A20]MTX to compete with [125I]apamin for binding
onto rat brain synaptosomes. Fig. 4 shows an
[A12,A20]MTX-induced, concentration-dependent, inhibition
of [125I]apamin binding with a IC50 of 310 þ 100 nM. In com-
parison, synthetic MTX and unlabeled apamin completely
inhibited [125I]apamin binding with IC50’s of 11 þ 10 nM and
0.52 þ 0.11 pM. This indicates that the proline substitutions in
MTX result in a 30-fold decrease in binding a⁄nity of the
peptide for SK type channels. This can be compared with the
9-fold reduction in a⁄nity observed for [Abu19, Abu34]MTX.
Next, we determined the inhibitory e¡ect of [A12,A20]MTX on
K currents that result from the expression of Shaker B, rat
Kv1.2 and Kv1.3 in Xenopus oocytes. Fig. 5A illustrates a
representative inhibition of Shaker B currents by 500 nM
[A12,A20]MTX. The extent of inhibition was identical for var-
ious membrane depolarization values demonstrating the lack
of strong voltage dependence in the peptide action. Dose-re-
sponse experiments demonstrate that [A12,A20]MTX inhibits
up to 94% Shaker B currents with an IC50 of 130 þ 123 nM
(n = 18; Fig. 5B). A similar maximal inhibition (92%) has also
been observed for sMTX, albeit with an IC50 of 2.5 nM which
corresponds to a 52-fold higher a⁄nity than that observed
with [A12,A20]MTX for Shaker B channels [13]. We also tested
the e¡ect of singly substituted analogs of MTX on Shaker
currents and observed IC50’s of 1.1 þ 0.7 nM for [A12]MTX
(n = 24) and 1.4 þ 1.4 nM for [A20]MTX (n = 26) (data not
shown). These values are thus similar to sMTX and suggest
that in the case of Shaker channel, disul¢de bridge rearrange-
ment of MTX does not a¡ect blocking properties. In the case
of the [A12,A20]MTX analog, there are probably some greater
alterations in toxin structure which may be responsible for its
decreased potency in blocking Shaker channels. As for sMTX,
the [A12,A20]MTX analog had no e¡ect on rat Kv1.1 (data
not shown). It retained a signi¢cant activity onto rat Kv1.2
channels, as it inhibits 59 þ 23% of the K currents with an
IC50 of 0.68 þ 0.06 nM (n = 12). This a⁄nity of [A12,A20]MTX
for Kv1.2 is about 10-fold lower than the IC50 of 0.06 nM
reported for sMTX [12]. We were unable to measure a precise
binding a⁄nity of [A12,A20]MTX for rat Kv1.3 although it
appeared to block the current to a small extent (less than
Fig. 3. Conformational analysis of [A12,A20]MTX versus MTX. A: 1D NMR spectra of synthetic MTX (left) and its structural analog,
[A12,A20]MTX (right). For conditions, see Section 2. B: Ribbon representations of the 3D structure in solution of synthetic MTX (left, from
the PDB), and the averaged minimized structure of an [A12,A20]MTX model (right).
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20%, n = 8) at high micromolar concentrations. A gross esti-
mate of binding a⁄nities suggests that there is also a 10-fold
decrease in a⁄nity induced by the proline substitutions.
Several novel information emerge from this study. First, it
appears that the two proline residues in positions 12 and 20
play a pivotal role at least with regard to the disul¢de bridge
organization of MTX. Substitutions of these imino acid resi-
dues by alanyl induce a shift from the MTX half-cystine pair-
ings (C1^C5, C2^C6, C3^C4 and C7^C8) towards a Pi1/
HsTx1 disul¢de bridge pattern (C1^C5, C2^C6, C3^C7 and
C4^C8). The intimate molecular mechanism(s) underlying
these changes in disul¢de bridging have not yet been eluci-
dated; however, one can envision that the two proline resi-
dues strongly favor the formation of the ‘non-conventional’
C3^C4 pairing in natural MTX, and that selective point mu-
tations of these residues result in removal of such key prolyl-
associated structural constraints. In turn, this change would
favor a structural organization of the toxin towards a more
‘conventional’ disul¢de bridge arrangement. Second, it is
noteworthy that disul¢de bridge reorganization in MTX re-
sults in a repositioning of the axis of the K-helix with regard
to that of the L-sheet. Such a repositioning was not only
observed in [A12,A20]MTX (shift from an angle of 50‡ to
25‡), but also in [Abu19,Abu34]MTX (shift from an angle of
50‡ to 0‡). These results are to be opposed to the observation
that the fourth disul¢de bridge in HsTx1 contributes little to
the structure of HsTx1 [14]. Of interest for MTX, the relative
orientation of the K-helix with regard to the main axis of the
L-sheet measured on all available scorpion toxins from the
Protein Data Bank ¢les ranges from 0‡ to 70‡, making this
feature amino acid sequence-dependent. Our data strongly
reinforce such an hypothesis. In addition, these data point
out that the relative positions of half-cystine residues within
the whole sequence are not the sole determinant guiding the
disul¢de bridge framework and K-helix positioning. This re-
arrangement in disul¢de bridges, accompanied by a reorienta-
Fig. 4. Inhibition of [125I]apamin binding onto rat brain synapto-
somes by unlabeled apamin, sMTX and [A12,A20]MTX. Dose-de-
pendent inhibitions of [125I]apamin binding are ¢tted by the equa-
tion y = a/[1+exp(3(x3IC50)/b)] with IC50 values of 310 þ 100 nM
([A12,A20]MTX), 11 þ 10 nM (sMTX) and 0.52 þ 0.11 pM (unlabeled
apamin). B0 is the binding of [125I]apamin in the absence of ligand,
and B is the binding in the presence of the indicated concentration
of competitors. Non-speci¢c binding, less than 10%, was subtracted
for the calculation of the ratios.
Fig. 5. [A12,A20]MTX is a Kv type K channel blocker. A: Oocyte expressing Shaker B K currents recorded under two-electrode voltage
clamp. Currents were obtained by depolarization from 390 mV to various potentials (from 340 to 70 mV by 10 mV increments). Left: control
currents. Right: currents during superfusion of 500 nM [A12,A20]MTX, illustrating over 80% block. B^D: Dose-dependent inhibition curves
of Shaker B, rat Kv1.2 and rat Kv1.3 currents by [A12,A20]MTX (¢lled circles). Dashed lines represent dose-dependent inhibition curves
for sMTX and are shown for comparison. Data points at the mean þ S.E.M. The solid lines for the data are from the equation y =
a/[1+exp(3(x3IC50)/b)] with IC50 values of 130 þ 123 nM (Shaker B, n = 18) and 0.68 þ 0.06 nM (rat Kv1.2, n = 12).
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tion of the K-helix, could be, in each case, linked to changes in
pharmacological sensitivity, suggesting that 3D repositioning
of key amino acid residues critical to K current blockage is
likely to occur. The change in angle value between the K-helix
and the L-sheet is unlikely to fully support the variation in
peptide pharmacology towards Kv1.3. In [Abu19;34]MTX,
with an angle value of 0‡, we noticed an enhancement of
current blockade [12]. In contrast, a reduction in blockade
potency was observed for [A12,A20]MTX in spite of a similar
reduction in the angle between the two secondary structures.
Whatever the observed changes, these observations are all
consistent with the assumption that the integrity of the
MTX C-terminus is pivotal to Kv1.3 pharmacology [15].
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